As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and raised the price target from $26 to …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) received another set of praises from analysts at Roth Capital, in addition to analysts at Cowen and Brean Capital.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it is offering 7.
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of …
Shares of Celldex Therapeutics (NASDAQ: CLDX) shot up about 17.5% in trading on February 23rd following the company’s announcement that it was granted FDA approval …
Celldex Therapeutics, Inc. (Nasdaq:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2014.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares are up 17.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced that the U.
Cowen’s healthcare analyst Boris Peaker came out with an update on Celldex Therapeutics (NASDAQ:CLDX), following yesterday’s news that the company and partner Bristol Myers-Squibb initiated a phase 1/2 …
